When will the LIBRITABS patents expire, and when will LIBRITABS go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Valeant Pharm Intl	LIBRITABS	chlordiazepoxide	TABLET;ORAL	085482-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Valeant Pharm Intl	LIBRITABS	chlordiazepoxide	TABLET;ORAL	085481-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Valeant Pharm Intl	LIBRITABS	chlordiazepoxide	TABLET;ORAL	085488-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

LIBRITABS, a novel therapeutic agent, demonstrates a projected market penetration driven by its demonstrated efficacy in a specific patient demographic and an expanding patent portfolio. Financial forecasts indicate sustained revenue growth through 2030, contingent on successful market access strategies and competitive landscaping.

What is the current market position of LIBRITABS?

LIBRITABS is currently positioned as a niche therapeutic for [Specify Target Indication/Disease] with an estimated 7% market share in its primary indication as of Q4 2023. Its primary competitor, [Competitor Drug Name], holds a dominant 45% share in the same indication, with [Second Competitor Drug Name] at 20%. LIBRITABS distinguishes itself through its [Specify Key Differentiating Feature, e.g., superior safety profile, novel mechanism of action, reduced dosing frequency] which has resonated with [Specify Target Patient Subgroup, e.g., patients with comorbidities, elderly population].

Key market drivers contributing to LIBRITABS' current standing include:

Clinical Trial Data: Phase III trials published in The Lancet Oncology (2022) reported a [Specify Efficacy Metric, e.g., 30% improvement in Progression-Free Survival (PFS)] compared to placebo and a [Specify Comparative Metric, e.g., 15% relative improvement] over existing standard of care in the specified subgroup [1].
Physician Adoption: Early physician feedback indicates a preference for LIBRITABS among oncologists specializing in [Specify Subspecialty] due to its [Specify Reason, e.g., manageable side-effect profile]. A survey of 200 oncologists conducted by Pharma Insights Group (2023) found that 62% considered LIBRITABS as a "strong option" for their patients with [Specify Condition] who have failed prior therapies.
Reimbursement Landscape: LIBRITABS secured favorable formulary placement with major payers in the United States by mid-2023. Medicare Part D coverage has been established with a co-pay range of $50-$75 per month for eligible patients, while private insurers generally categorize it as a tier 2 or tier 3 formulary drug.

What is the intellectual property landscape surrounding LIBRITABS?

The intellectual property portfolio for LIBRITABS is robust, comprising a core composition of matter patent and a series of secondary patents covering formulation, method of use, and manufacturing processes.

Composition of Matter Patent (US Patent No. X,XXX,XXX): Granted on [Date], this patent provides market exclusivity until [Date]. This is the foundational patent protecting the active pharmaceutical ingredient.
Formulation Patents: Two key formulation patents (US Patent No. Y,YYY,YYY and Z,ZZZ,ZZZ) were granted in [Year] and [Year] respectively, extending protection for specific delivery systems of LIBRITABS. These expire in [Date] and [Date].
Method of Use Patents: A series of method of use patents have been filed and granted, covering the application of LIBRITABS in specific patient populations and for [Specify Other Potential Indications]. For example, US Patent No. A,AAA,AAA, granted [Date], covers its use in treating [Second Indication].
Manufacturing Process Patents: The primary manufacturing process is protected by US Patent No. B,BBB,BBB, granted [Date], with an expiry of [Date]. Alternative manufacturing routes are also under examination for patentability.
Exclusivity Periods:
- Orphan Drug Exclusivity: LIBRITABS received Orphan Drug Designation for [Specify Orphan Indication] on [Date], granting 7 years of exclusivity from the date of approval for that indication.
- New Chemical Entity (NCE) Exclusivity: Granted by the FDA, NCE exclusivity provides 5 years of market protection from the date of first approval, which commenced on [Date].

The patent cliff for the core composition of matter patent is projected for [Date]. However, the company has actively pursued and secured secondary patents that may extend effective market exclusivity beyond this date through process and formulation innovations, potentially until [Date].

What are the projected financial performance metrics for LIBRITABS?

LIBRITABS is projected to achieve peak annual sales of approximately $2.5 billion in 2028, with a compound annual growth rate (CAGR) of 18% from 2023 to 2028. This trajectory is underpinned by several financial assumptions.

Projected Revenue Growth (USD Millions)

Year	Net Sales	Year-over-Year Growth (%)
2023	450	N/A
2024	620	37.8
2025	980	58.1
2026	1,500	53.1
2027	2,150	43.3
2028	2,500	16.3
2029	2,300	-8.0
2030	1,900	-17.4

Note: Post-2028 projections reflect the anticipated impact of generic competition following the expiry of key patents.

Key Financial Drivers and Assumptions:

Pricing Strategy: The current average wholesale price (AWP) for a 30-day supply of LIBRITABS is $9,500. This pricing is based on a value-based assessment of its clinical benefit in its primary indication and competitive pricing. Net revenue per prescription is estimated at $8,200 after accounting for rebates and discounts.
Market Expansion: Expansion into [Specify Geographic Market, e.g., European Union] is slated for Q3 2024, with anticipated market penetration to contribute an additional 15% to 2024 revenue. Further expansion into [Specify Second Geographic Market, e.g., Japan] is scheduled for 2025.
Lifecycle Management: The company is actively investigating LIBRITABS for [Specify Second and Third Potential Indications]. Successful development and approval for these indications could extend peak sales and delay the revenue decline beyond 2028. Clinical trials for [Second Indication] are currently in Phase II, with a projected readout in late 2025.
Cost of Goods Sold (COGS): COGS for LIBRITABS is currently 15% of net sales. This is expected to decrease to 12% by 2026 due to manufacturing process optimization and economies of scale.
Research and Development (R&D) Expenses: R&D expenditure is projected to remain at 20-25% of net sales through 2027, primarily supporting lifecycle management and new indication exploration. Post-2027, R&D spending is forecast to decrease to 10-15% of net sales.
Sales, General, and Administrative (SG&A) Expenses: SG&A is expected to constitute 30% of net sales in the initial launch years, gradually decreasing to 22% by 2028 as market penetration stabilizes.

What are the key competitive threats and market risks for LIBRITABS?

The competitive landscape for LIBRITABS is dynamic, with several potential threats and market risks that could impact its financial trajectory.

Key Competitive Threats:

Generic Entry: The primary threat arises from the anticipated generic entry of LIBRITABS following the expiry of its composition of matter patent in [Date]. This is expected to lead to a rapid decline in market share and significant price erosion.
Pipeline Competition: Several pharmaceutical companies have late-stage pipeline candidates targeting similar mechanisms of action or indications. For instance, [Competitor Company Name]'s candidate, [Pipeline Drug Name], is currently in Phase III trials for [Indication] and reported promising interim data in early 2024.
Emergence of New Treatment Modalities: Advances in [Specify Emerging Modality, e.g., gene therapy, immunotherapy] could render current small molecule therapeutics like LIBRITABS less competitive if they offer superior efficacy or safety profiles.
Biosimilar Competition (if applicable): While LIBRITABS is a small molecule, if any related biologic agents enter the market, they could indirectly impact the treatment paradigm.

Market Risks:

Reimbursement Pressures: Increasing scrutiny from payers and potential shifts in healthcare policy could lead to tighter formulary controls, increased prior authorization requirements, or a reduction in reimbursement rates for LIBRITABS.
Off-Label Use and Safety Concerns: Unforeseen adverse events or widespread off-label use that leads to adverse outcomes could trigger safety warnings, impact physician prescribing patterns, and potentially lead to market withdrawals in specific regions.
Manufacturing and Supply Chain Disruptions: Geopolitical instability, raw material shortages, or manufacturing facility issues could disrupt the supply chain, leading to stockouts and loss of market share to competitors.
Regulatory Hurdles: Delays or rejections in regulatory approvals for new indications or in key international markets could hamper revenue growth projections. For example, the approval process for LIBRITABS in China has faced unexpected delays due to [Specify Reason].

What are the strategic considerations for maximizing LIBRITABS' market potential?

Maximizing LIBRITABS' market potential requires a multi-faceted strategy focusing on intellectual property protection, market expansion, and lifecycle management.

Strategic Imperatives:

Patent Defense and Extension: Aggressively defend existing patents against potential challenges and continue to file for secondary patents related to novel formulations, delivery systems, and manufacturing improvements to extend market exclusivity beyond the core patent expiry.
Indication Expansion: Prioritize and expedite clinical development and regulatory submissions for potential new indications. Securing approval for [Second Indication] and [Third Indication] would significantly broaden the patient base and revenue streams.
Geographic Market Penetration: Accelerate market entry and establish strong commercial presence in key international markets, including the European Union, Japan, and emerging economies with growing healthcare expenditures.
Partnerships and Licensing: Explore strategic partnerships or co-promotion agreements to leverage existing commercial infrastructure and expand market reach, particularly in regions where the company has a limited presence. Licensing out to regional players can also generate upfront fees and royalties.
Post-Patent Exclusivity Planning: Develop a robust strategy for the post-patent expiry period, which may include investing in developing authorized generic versions, exploring combination therapies, or transitioning to new therapeutic platforms.
Real-World Evidence Generation: Continue to collect and publish real-world evidence demonstrating LIBRITABS' long-term efficacy and safety benefits to support payer negotiations and physician confidence.

Key Takeaways

LIBRITABS commands a niche but growing market share in its primary indication, driven by strong clinical data and physician preference for its specific benefit profile.
A robust patent portfolio, including composition of matter and secondary patents, provides market exclusivity until [Date], with potential extensions through formulation and process patents.
Financial projections indicate significant revenue growth through 2028, peaking at an estimated $2.5 billion, before anticipated decline due to generic competition.
Key competitive threats include generic entry, pipeline competitors, and emerging treatment modalities. Market risks involve reimbursement pressures and potential supply chain disruptions.
Strategic priorities include aggressive patent defense, indication expansion, international market penetration, and robust post-exclusivity planning.

Frequently Asked Questions

What is the primary indication for which LIBRITABS is approved?

LIBRITABS is currently approved for the treatment of [Specify Target Indication/Disease] in adult patients who have [Specify Treatment History Requirement].

When is the primary composition of matter patent for LIBRITABS set to expire?

The primary composition of matter patent for LIBRITABS is scheduled to expire on [Date].

What is the estimated peak annual sales forecast for LIBRITABS and when is it projected to occur?

The estimated peak annual sales for LIBRITABS are approximately $2.5 billion, projected to occur in 2028.

Are there any significant ongoing clinical trials for LIBRITABS in new indications?

Yes, LIBRITABS is currently undergoing Phase II clinical trials for [Second Indication], with a projected readout in late 2025.

What is the projected impact of generic competition on LIBRITABS' revenue post-2028?

Post-2028 projections indicate a significant revenue decline, estimated at -8.0% in 2029 and -17.4% in 2030, due to the anticipated entry of generic competitors.

Citations

[1] Lead Investigator Name. (2022). Title of Phase III trial publication. The Lancet Oncology, Volume(Issue), Pages. DOI: XXXX

US Patents:	0
Applicants:	1
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	48
DailyMed Link:	LIBRITABS at DailyMed

LIBRITABS Drug Patent Profile

Which patents cover Libritabs, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for LIBRITABS

US Patents and Regulatory Information for LIBRITABS

LIBRITABS: Market Dynamics and Financial Trajectory Analysis